chartexchange

ANAB270521C00030000
ANAB May 21 2027 30.00 Call
optionOPRA

InactiveOct 27, 2026
22.50USD+12.500%(+2.50)1Vol0OI
Loading…
Underlying
Underlying Price
$47.40
Type
Call
Strike
30
Expiration
May 21, 2027
DTE
183d
Moneyness
ITM
Intrinsic
$17.40
ANAB 30 Call Across Expirations
ExpirationDTELastChangeVolOpen Int
Nov 20, 20261d——00
Dec 18, 202629d——00
Jan 15, 202757d——00
Feb 19, 202792d$42.10+6.58%21
May 21, 2027183d$22.50+12.50%10
ANAB Nearby Strikes · May 21, 2027
StrikeLastChangeVolOpen IntMoneyness
25 C——00ITM
30 C$22.50+12.50%10ITM
35 C——00ITM
40 C——00ITM
45 C$10.50-18.92%1011ITM
50 C$9.40-23.58%15OTM
55 C$8.00+0.00%22OTM
60 C$7.50+50.00%24OTM
ANAB Profile

founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio's proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c